Does posttransplant anemia at 6 months affect long-term outcome of live-donor kidney transplantation? A single-center experience.
OBJECTIVE
Posttransplantation anemia (PTA) frequently occurs. We aimed to assess the prevalence of anemia at 6 months of transplantation in patients under different protocols of immunosuppression, and to determine the impact of anemia on long-term patient and graft survival.


METHODS
We included 832 renal transplant recipients who were categorized at 6 months according to hemoglobin (Hb) level into two groups: the first group, with Hb >13 g/dl in males and >12 g/dl in females (group I, 385 cases); and the second group, with Hb <13 g/dl in males and <12 g/dl in females (group II, 447 cases). We compared the two groups regarding posttransplant complications as well as patient and graft survival.


RESULTS
Although there was no significant difference between the two groups regarding acute rejection episodes, chronic allograft nephropathy was significantly higher in the anemic group. Other posttransplant medical complications were comparable in both groups. Graft survival was significantly higher in the nonanemic group. However, no difference in patient survival was detected.


CONCLUSIONS
From this study, we can conclude that prevalence of PTA is high, especially in females and those receiving calcineurine inhibitors (CNI) and mycophenolate mofetil (MMF), and that it was associated with poorer graft outcome but with no effect on patient survival.
Gheith
Osama
O
Urology and Nephrology Center, Mansoura University, 17 gomhoreya at Mansoura, Mansoura, Egypt. ogheith@yahoo.com.
Wafa
Ehab
E
Urology and Nephrology Center, Mansoura University, 17 gomhoreya at Mansoura, Mansoura, Egypt.
Hassan
Nabil
N
Urology and Nephrology Center, Mansoura University, 17 gomhoreya at Mansoura, Mansoura, Egypt.
Mostafa
Amani
A
Urology and Nephrology Center, Mansoura University, 17 gomhoreya at Mansoura, Mansoura, Egypt.
Sheashaa
Hussein A
HA
Urology and Nephrology Center, Mansoura University, 17 gomhoreya at Mansoura, Mansoura, Egypt.
Mahmoud
Khaled
K
Urology and Nephrology Center, Mansoura University, 17 gomhoreya at Mansoura, Mansoura, Egypt.
Shokeir
Ahmed
A
Urology and Nephrology Center, Mansoura University, 17 gomhoreya at Mansoura, Mansoura, Egypt.
Ghoneim
Mohamed A
MA
Urology and Nephrology Center, Mansoura University, 17 gomhoreya at Mansoura, Mansoura, Egypt.
D000293:Adolescent; D000328:Adult; D000740:Anemia / Q000097:blood / Q000209:etiology* / Q000401:mortality; D015415:Biomarkers / Q000097:blood; D003401:Creatine / Q000097:blood; D005260:Female; D006084:Graft Rejection / Q000097:blood / Q000209:etiology* / Q000401:mortality; D006085:Graft Survival; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects; D053208:Kaplan-Meier Estimate; D016030:Kidney Transplantation / Q000009:adverse effects* / Q000401:mortality; D019520:Living Donors; D008297:Male; D018570:Risk Assessment; D012307:Risk Factors; D012737:Sex Factors; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
D015415:Biomarkers; D006454:Hemoglobins; D007166:Immunosuppressive Agents; D003401:Creatine